Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. - Wikidata - wikimedia - TriplyDB

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

http://www.wikidata.org/entity/Q34331649

about

Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelines Acute management of unstable angina and non-ST segment elevation myocardial infarction Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review The "smoker's paradox" in patients with acute coronary syndrome: a systematic review Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism Therapeutic approaches in arterial thrombosis Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome Normalization of platelet reactivity in clopidogrel-treated subjects Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Acute coronary syndromes: diagnosis and management, part I Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin Novel multi-modal strategies to promote brain and spinal cord injury recovery.Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation.Recent advances in antithrombotic therapy after acute coronary syndrome.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.Rectus sheath hematoma with low molecular weight heparin administration: a case series.Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years Dosing of unfractionated heparin in acute coronary syndromes.Effect of enoxaparin on clinical events after percutaneous coronary intervention.SBC guidelines on unstable angina and non-ST-elevation myocardial infarction: executive summary.Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes.A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients.Treatment of non-ST-elevation acute coronary syndrome in the elderly: current practice and future opportunities.Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.Coping with new challenges in acute coronary syndromes.Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals.

P2860

Q24653318-F41DD716-76B5-4A02-BB6B-FD69778BC35C Q26783157-C4CB3BB9-A070-4F89-A00A-B0B3055909D6 Q26853150-56E2A441-D236-4B27-95B6-E8ECB7627D61 Q26862694-F306B415-1C43-4809-8C20-1F9B030930A6 Q26992262-71318E8D-D10B-48A1-A41B-0AE98D6F3FAD Q27007476-0C219C1B-6DAC-4F77-9887-D03E08BF6D61 Q28079081-FBE4CC92-D1A0-4615-9C87-C397B277E760 Q28187576-0154F518-4B0E-4B02-9184-15E83E8539BC Q28213718-84E8CB59-788D-482E-B57A-C4DCB4828D87 Q28217935-1C527E5E-479C-4C03-AFB0-10AA190A865C Q30438893-18895BDC-5A5A-4F56-8964-6A645A665FCB Q30490718-2636531A-BF51-4C0D-A0B8-152CD8AF78DF Q31039802-0F13429F-52B6-4E74-843F-FC80466625CA Q33381356-086255E1-0F12-4CDF-A518-7C7683CFE9D0 Q33390906-583E0EC7-FC59-474E-AA4C-F9502544722D Q33433817-141BEE03-3BF6-4759-B2BF-AB627400B165 Q33590548-0F710F44-818F-409F-8BD0-737513C22F7A Q33685447-E4703530-8D2D-4A3E-A8AE-3AA2D38665F1 Q33728256-17719D70-E339-404A-88AF-F972C725E484 Q33750028-0DE0D04D-97C5-4428-A334-DA7A0B8D12E6 Q33750461-C28032A2-1A3D-44E4-A0A5-7F36F696E7C4 Q33797609-135F3D30-6C61-4C8D-8BB9-8D3AFFFC0AD7 Q34174194-07F27328-375E-46C1-BE1F-186D26682BDA Q34196711-D6171CBC-695A-41FC-9781-28BAA77EC02E Q34255603-10729E04-C1F3-40C1-BA39-CBCFE29CEC09 Q34415964-285EBF96-F4B1-48A5-BA2A-CF8727259469 Q34706540-86153231-D0EF-4483-AD20-39BFB029DCE2 Q34716730-122AAB2D-0231-4AF1-863A-900633AC3500 Q35826954-72C6CBFF-3B55-4C94-9572-71C0F41FACCC Q35883044-0C54E7F0-2203-44FB-A48B-6D70206C28E3 Q35976822-8FAB89A6-1799-4F9D-914D-F97AFD625E70 Q36046275-EE160DAE-4DB5-4E31-A8C3-6ABC3F718F4D Q36116996-FEBE4197-EE50-4A9D-AEA0-2D5592E62331 Q36141930-257F63DB-3897-4BDA-B0F3-2F8F7A926783 Q36363183-FF7BB626-DDFD-4A57-B8A7-20F20DA8E69A Q36369711-D1B9C9D0-B745-40A8-A89E-ADDC2A05117B Q36519924-CF0B0F8D-56F8-42D2-AD2A-A8A9013904A3 Q36575461-D61CF2B4-692F-4454-9824-80CEC6254F63 Q36608168-ABB8FADB-FAD7-47C1-B43E-1E89BBABE953 Q36634214-88698703-55A9-4541-8655-17F4A03EA9BA

P2860

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

http://www.wikidata.org/entity/Q34331649

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@ast

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@en

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@nl

type

label

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@ast

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@en

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@nl

prefLabel

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@ast

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@en

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@nl

P1433

Q34331649-D4C453A1-17D4-4BF7-A627-D79C1BC953C9

P1476

Q34331649-BC92ECF8-7AB7-4E25-9102-9A3212E101C2

P2093

Q34331649-0CC1C55E-EE2B-4C10-8B1F-D6AC8A8A6195

Q34331649-19AC5D46-367E-4D58-9D78-1E6D64B039F6

Q34331649-1B10D6CA-EB53-4E8B-8CB8-D722B445D7D2

Q34331649-34C073D0-8DD0-433C-A137-B733F8140613

Q34331649-373A24B9-1508-42F9-8729-78897EC2A625

Q34331649-3F11A136-3401-4EED-ADFA-775CDE00E3B7

Q34331649-4E7648E7-0328-42B3-ABF6-268BAE7A9669

Q34331649-5399250B-8D54-4720-90C2-8BF8583C4E04

Q34331649-57C04E27-1D28-419B-8262-5BFAAF3DC789

Q34331649-5B17D0E0-8266-4C6B-BEA9-0A47863ACE7C

P304

Q34331649-FEAA1F67-D16F-40DF-95C6-2096AE081E7E

P31

Q34331649-135692E5-A6E2-48D0-B609-75369833E9EF

P356

Q34331649-92B16FEC-5971-42F7-8809-B49EC4EB2E63

P407

Q34331649-5469DF26-5B25-4FF4-8832-25D8562137CA

P433

Q34331649-2E639D62-0DB5-474E-9814-D96657491DAF

P478

Q34331649-A3D5055B-3097-4611-8427-2D26F39AFBC3

P50

Q34331649-75E243E9-9739-4112-9C4D-EFCF2C99AB41

Q34331649-796CC644-0355-4A94-8E51-D8F348ABA28C

Q34331649-81E12EF3-8C45-4A13-8606-BB1FCAEDD452

Q34331649-90DBBA64-DB2D-4737-8DB9-CA1859FD7C50

Q34331649-FA6DF6E4-FE1A-4398-B87B-CD6AB8DB54A7

P577

Q34331649-E6263EEB-73BE-4BE4-A53C-5C026B4FFF78

P698

Q34331649-A6869A58-1398-45C2-A05F-004D37D7DEA8

P921

Q34331649-B86DC85A-2653-45A9-BEF3-370743EA5AAB

P356

P1433

Journal of the American Medical Association

P1476

Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.

@en

P2093

Alvaro Avezum

http://www.w3.org/2001/XMLSchema#string

Anatoly Langer

http://www.w3.org/2001/XMLSchema#string

Carl J Pepine

http://www.w3.org/2001/XMLSchema#string

Christopher C Nessel

http://www.w3.org/2001/XMLSchema#string

Cindy L Grines

http://www.w3.org/2001/XMLSchema#string

Dean J Kereiakes

http://www.w3.org/2001/XMLSchema#string

Dietrich C Gulba

http://www.w3.org/2001/XMLSchema#string

Ed Fry

http://www.w3.org/2001/XMLSchema#string

Enrique Gurfinkel

http://www.w3.org/2001/XMLSchema#string

Harvey White

http://www.w3.org/2001/XMLSchema#string

P304

45-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.292.1.45

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

292

http://www.w3.org/2001/XMLSchema#string

P50

Steven R Steinhubl

Robert A Harrington

Kenneth W Mahaffey

Elliott M Antman

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15238590

http://www.w3.org/2001/XMLSchema#string

P921